Is Dermata Therapeutics, Inc. (DRMA) a Buy, Sell, or Hold?
NASDAQ : DRMA
Dermata Therapeutics, Inc.
$1.28 USD
-$0.02 (-1.54%)
- Volume
- 49.1K
- Average Volume
- 70.88K
- Market Capitalization
- $872.39K
- P/E Ratio
- -0.24
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $7.50
- Year Low
- $1.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.09
| Source | Headline |
|---|---|
|
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 - - Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility - SAN DIEGO, CA / ACCESS Newswire / May 13, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2026. "Since announcing our strategic pivot in September 2025, we have made meaningful progress toward becoming a direct-to-consumer commercial skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO. accessnewswire.com - 2026-05-13 16:05:00 |
